FDA & AABB in Practice

The finish line

By the end of this course you can design a defensible internal audit program, prepare a system or process for an FDA inspection or AABB (Association for the Advancement of Blood & Biotherapies) assessment, and respond to a Form FDA 483 observation. You’ll know exactly what FDA can walk in and ask for, what happens after an inspection ends, when a problem becomes a recall and which class it gets, when a deviation becomes a report FDA actually receives, and what an AABB assessor expects to see that an FDA investigator doesn’t.

This course’s scenario picks up exactly where data-integrity-and-records left its own self-assessment, DI-0301: Lakeshore’s next AABB reassessment is now close enough to have a real timeline, and a routine FDA inspection could land before it. Everything DI-0301 found — DED-0458’s still-open “accurate” question, LAB-07’s documented-fitness-for-use gap, the cumulative deferred-donor record’s monthly-floor-versus-real-risk finding — is still sitting on the Director’s desk. This course is where those findings meet an actual outside reviewer.

Before you start

This course assumes the three foundations and three earlier courses:

• Reading a CFR citation, Regulatory landscape orientation, and Risk and controls vocabulary.
• Quality System Essentials, especially Deviations and nonconformances (already teaches 606.171’s reportability test and 45-day clock in full — this course picks up exactly where that module stopped, at the point of actually filing a report) and Internal audits and management review (already teaches what an internal audit and a management review are — this course builds the program design layer on top: auditor independence, scheduling, sampling, grading).
• CSV & BECS and Data Integrity & Records, both for their closed and still-open findings this course’s final module puts in front of an inspector.

The six modules

Each module is one sitting, and each has its own finish line.

1. FDA inspection authority and outcomes. Name what FDA’s own inspection authority actually lets an investigator do and ask for, explain Form FDA 483’s real purpose and legal weight, and name the three possible outcomes an inspection can end in.
2. Warning Letters and recalls. Explain when a 483 escalates into a Warning Letter, and sort any product problem into the right recall classification — Class I, II, or III — using FDA’s own health-hazard test, not a guess at severity.
3. Filing a Biological Product Deviation Report. Pick up exactly where an earlier course left off — the reportability determination — and finish the job: file the report itself, on the right form, to the right office, in the right window.
4. The AABB assessment process. Walk Lakeshore through both phases of an AABB reassessment — self-assessment and on-site — and say precisely what an assessor expects that an FDA investigator doesn’t.
5. Designing an internal audit program. Build the program an internal audit needs to actually hold up: auditor independence and competency, risk-based scheduling, real evidence sampling, and a nonconformance grading scale with teeth.
6. Mock inspections: presenting IT and BECS evidence. Put everything this course and the last two taught in front of a reviewer who’s actually in the room — and finally resolve, out loud, what’s still open from data-integrity-and-records.

A note on sources

This course leans on a wider range of source types than most in this curriculum:

• Statute: 21 U.S.C. 374 (FD&C Act § 704) — FDA’s actual inspection-authority law, quoted from an excerpt saved locally, not the full, heavily amended section.
• FDA regulation: 21 CFR Part 7 (recalls) and 606.171 (biological product deviation reports), quoted from local copies.
• FDA public/informational pages and presentations: Form 483’s own description, and the NAI/VAI/OAI inspection-outcome classification — verified from FDA’s own public materials, with one source’s genuine scope limit (a clinical-trial-inspection presentation, used only for its general classification scheme) flagged honestly rather than overstated.
• AABB’s own public program description: the accreditation process itself, never AABB Standards text, which stays copyrighted and unquoted throughout, as in every course before this one.
• Industry practice: the ASQ (American Society for Quality) Certified Quality Auditor body of knowledge’s themes — independence, competency, sampling, grading — described in this course’s own words, never quoted or cited by exam-objective number.

Modules appear in the sidebar as they’re built.